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T
he continuing appearance of multidrug-resistant
bacteria poses a signiﬁcant threat to human
health and presents an urgent need for the devel-
opment of new antimicrobial drugs. Lantibiotics, a di-
verse and promising class of antimicrobial peptides pro-
duced by a variety of bacteria, display a broad spectrum
of activity (1, 2). Over 50 members have been identi-
ﬁed to date, with several displaying potent antimicro-
bial activity at nanomolar levels against nosocomial
pathogens such as methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant enterococci (VRE),
and oxacillin-resistant Gram-positives (2, 3). Impor-
tantly, development of signiﬁcant levels of resistance
has not been observed for nisin, the best-studied lan-
tibiotic that has been used worldwide against food-born
pathogens for more than four decades (4).
Lantibiotics are ribosomally synthesized as inactive
precursors that undergo extensive enzyme-mediated
post-translational modiﬁcations to their biologically ac-
tive forms (3). The inactive precursor peptides (LanA)
consist of an unmodiﬁed N-terminal leader sequence
and a C-terminal structural region that is modiﬁed to the
mature lantibiotic. The molecular details of the function
of the leader sequence remain unclear (5); however, in
addressed cases it is required for complete maturation
of the structural region and for secretion of the bioactive
product (3). Modiﬁcations observed in all lantibiotics in-
volve the dehydration of select serine and threonine
residues to produce dehydroalanine (Dha) and dehydro-
butyrine (Dhb) residues, respectively. Following dehy-
dration, an intramolecular Michael-type addition of cys-
teine thiols onto the unsaturated amino acids generates
lanthionine (Lan) and methyllanthionine (MeLan)
thioether rings (1).
Two-peptide lantibiotics function through the activi-
ties of two peptides whereby each peptide contributes
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ABSTRACT Haloduracin, a recently discovered two-peptide lantibiotic com-
posed of the post-translationally modiﬁed peptides Hal and Hal, is shown to
have high potency against a range of Gram-positive bacteria and to inhibit spore
outgrowth of Bacillus anthracis. The two peptides display optimal activity in a 1:1
stoichiometry and have efﬁcacy similar to that of the commercially used lantibiotic
nisin. However, haloduracin is more stable at pH 7 than nisin. Despite signiﬁcant
structural differences between the two peptides of haloduracin and those of the
two-peptide lantibiotic lacticin 3147, these two systems show similarities in their
mode of action. Like Ltn, Hal binds to a target on the surface of Gram-positive
bacteria, and like Ltn, the addition of Hal results in pore formation and potas-
sium efﬂux. Using Hal mutants, its B- and C-thioether rings are shown to be im-
portant but not required for bioactivity. A similar observation was made with mu-
tants of Glu22, a residue that is highly conserved among several lipid II-binding
lantibiotics such as mersacidin.
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tems, two prepeptides are ribosomally synthesized as
inactive precursors (LanA1 and LanA2), which are both
enzymatically modiﬁed to their mature, bioactive forms
(Lan and Lan). For all currently known two-peptide
lantibiotics, the dehydration of hydroxyl-amino acids
and subsequent cyclization to form (methyl)lanthionine
residues results from the actions of a bifunctional modi-
ﬁcation enzyme termed LanM. In most two-peptide sys-
tems, the sequence homology between the LanA1 and
LanA2 prepeptides is low; therefore two different bifunc-
tional enzymes (LanM1 and LanM2) each act speciﬁ-
cally on only one of the prepeptides (6, 7). The modi-
ﬁedLanA1andLanA2prepeptidesarefurtherprocessed
by a LanT protein, which removes the leader peptides
and secretes the ﬁnal products. The mature peptides of
several two-peptide systems share structural and se-
quence homology with known single-peptide lantibiot-
ics. The mature -peptides resemble the globular lan-
tibiotic mersacidin with several fused thioether rings,
whereas the mature -peptides are typically elongated
and more ﬂexible (8, 9) (Figure 1).
Both nisin (10) and mersacidin (11) target the
membrane-bound cell wall precursor lipid II, resulting
in the inhibition of peptidoglycan
biosynthesis (12) and, for nisin
but not mersacidin, pore forma-
tion (13). Binding to lipid II inhib-
its peptidoglycan biosynthesis by
physical sequestration, prevent-
ing the actions of transglycosy-
lase and transpeptidase enzymes
that polymerize lipid II and cross-
link the glycan chains of the na-
scent cell wall, respectively (13).
In a second mode of action, lipid
II is utilized as a docking mol-
ecule for the generation of de-
ﬁned and stable pores that result
in membrane damage and depo-
larization and ultimately cell
death (14). An additional activity
for several lantibiotics including
nisin is the ability to prevent
spore outgrowth of Gram-positive
bacteria (15, 16). A recent study
suggested that inhibition of out-
growth is directly related to the
ability of the lantibiotic to induce damage to the mem-
brane of germinating spores, thereby preventing the es-
tablishment of oxidative metabolism and a membrane
potential (17).
Haloduracin,atwo-peptidelantibioticrecentlydiscov-
ered by genome mining, is produced by the Gram-
Figure 1. Structures of haloduracin, lacticin 3147, nisin, and mersacidin. Shaded circles of Hal indicate
residues that were mutated in this study (Glu22, Cys23, and Cys27). Ala-S-Ala represents lanthionine,
Abu-S-Ala represents methyllanthionine, and OBu represents 2-oxobutyryl.
Figure 2. Isobologram indicating the concentrations and
ratio of Hal and Hal required to inhibit the growth of
the indicator strain Lactococcus lactis HP.
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C-125 (6, 18). The lantibiotic consists of two post-
translationally modiﬁed peptides, Hal and Hal. Here
we describe studies investigating the mode of action of
haloduracin and compare it to nisin, the prototypical
lantibiotic.
RESULTS AND DISCUSSION
Haloduracin Peptides Function Optimally at a 1:1
Ratio. Prior to assessing the speciﬁc activity of halodu-
racin against a panel of bacterial strains, the ratio of
Hal and Hal that yields maximum bioactivity was es-
tablished. For this purpose, the ability of Hal and Hal
to inhibit cell growth at varying concentrations and ra-
tios was examined. As indicated by the resultant isobo-
logram (Figure 2), haloduracin is active at nanomolar
levels against the indicator strain Lactococcus lactis HP,
and Haland Haldisplay optimal activity at a 1:1 ratio.
This ratio was determined as the lowest concentration
of individual Hal or Hal peptide that when combined
caused essentially complete growth inhibition (deﬁned
as 90%). The optimal synergy of Hal and Hal at a
1:1 ratio is shared with other two-peptide lantibiotic sys-
tems such as staphylococcin C55, plantaricin W, and
lacticin 3147 (19−21).
Although the haloduracin peptides are most active
in combination, at much higher concentrations both
Hal and Hal displayed independent activity against
the highly susceptible L. lactis HP strain. Using liquid
media growth assays, Hal and Hal had independent
TABLE 1. Comparison of haloduracin and nisin activities
Speciﬁc activity of haloduracin and nisin assessed by liquid growth inhibition assay
Haloduracin Nisin
Strain Source IC50 (nM) MIC (nM) IC50 (nM) MIC (nM)
Lactococcus lactis HP ATCCa 11602 29  21 73.4 14  5 32.2
Lactococcus lactis 481 CNRZb 481 63  24 195 68  6 127
Lactococcus lactis 11454 ATCC 11454 308  13 625 1,759  400 2,800
Vancomycin-resistant Enterococcus faecium C33105c 265  15 781 4,953  187 12,500
Bacillus anthracis Sterne 7702 Gut et al.d 363  54 677 311  216 417
Bacillus subtilis ATCC 6633 262  54 469 414  165 820
methicillin-resistant Staphylococcus aureus C5c 2,616  396 4,690 1,459  7 1,560
Staphylococcus aureus ATCC 12600 1,144  290 1,560 2,205  523 4,690
Staphylococcus epidermidis 15X Ekkelenkamp et al.e 273  23 313 368  152 508
Micrococcus luteus ATCC 4698 520  17 1,250 266  92 410
Streptococcus mutans ATCC 25175 1,837  417 2,500 5,394  732 12,500
Activity assessed by agar diffusion growth inhibition assay
Strain Source Haloduracin Nisin
Lactococcus lactis 117 CNRZ 117 
Bacillus subtilis DB104 Kawamura et al.f 
Bacillus subtilis LH45 Liu et al.g 
Bacillus cereus Z4222 INRAh Z4222 
Bacillus cereus TZ415 INRA TZ415 
Enterobacter cloacae 10-19C ATCC 29893 
Escherichia coli DH5 UIUC-CMFi 
aATCC: American type Culture Collection. bCNRZ: National Centre for Zootechnical Research. cClinical isolates from Carle Foundation Hospi-
tal(Urbana,IL). dReference17. eReference43. fReference44. gReference45. hINRA:InstitutNationaldelaRechercheAgronomique. iUIUC-
CMF: University of Illinois Urbana-Champaign Cell and Media Facility.
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tively, corresponding to a 50- to 100-fold decrease in ef-
ﬁcacy as compared to when the peptides were used to-
gether (Table 1). Though further experiments will be
necessary to fully identify how these peptides are able
to possess bioactivity in the absence of their counter-
part, we speculate on the basis of the structural similar-
ity of Hal with mersacidin (Figure 1) that Hal likely
binds to lipid II, thereby preventing peptidoglycan bio-
synthesis. Hal may exert its independent activity
through a mechanism similar to that of nisin in the ab-
sence of lipid II, in which the cationic Hal peptide
binds to anionic lipids of the cell membrane and the ag-
gregationofHalmonomerscausesthetransientforma-
tion of pore-like structures in the bacterial cell mem-
brane (13).
Comparison of the Antimicrobial Potency of
Haloduracin and Nisin. Agar diffusion growth inhibition
assays were performed against a panel of Gram-positive
and Gram-negative bacteria to obtain qualitative infor-
mation regarding their sensitivity to treatment with halo-
duracin and nisin. These preliminary studies provided
a binary outcome of either cell growth inhibition or pro-
liferation. Strains that showed susceptibility toward
haloduracin and nisin were subjected to growth inhibi-
tion assays in liquid media from which quantitative IC50
valuesweredetermined.Haloduracinandnisinshareda
similar spectrum of inhibitory activity against a wide
range of Gram-positive organisms but lacked potency
against the Gram-negative bacteria tested (Table 1). The
concentrations of haloduracin and nisin required to in-
hibit several strains revealed that the effectiveness of
the antimicrobial peptides is target-strain-dependent.
For example, L. lactis HP was quite sensitive to both lan-
tibiotics with IC50 values in the low-nanomolar range
(29  21 and 14  5 nM for haloduracin and nisin, re-
spectively). Some strains were more sensitive to halodu-
racin than to nisin (vancomycin-resistant Enterococcus)
and vice versa (Micrococcus luteus). However, in most
cases, only a 2- or 3-fold difference was observed in the
IC50 values of haloduracin and nisin against a particular
strain, and overall, haloduracin and nisin activity was
roughly equivalent against the panel of strains exam-
ined in this study.
Enhanced Stability of Haloduracin as Compared
with Nisin. Nisin shows promising activities in vitro and
in mouse models against several clinically relevant bac-
teria strains (22); however, its inherent chemical insta-
bility (23, 24) and poor solubility at physiological pH
have prevented therapeutic development. Nisin is pro-
duced by acidophilic Lactococcus lactis strains that grow
and produce the compound in highest quantities in an
acidic environment. Accordingly, nisin has been shown
to exhibit highest solubility and stability at low pH (25).
Anumberofdegradationproductsofnisinhavebeenre-
ported (23, 24, 26). In a previous study, nisin stability
was systematically monitored in low buffer concentra-
tions over a pH range of 28. The results showed that
nisin is most stable at pH 3, and its stability was drasti-
Figure 3. Haloduracin displays greater stability than nisin at
physiological pH. (a) Assessment of relative stabilities of Hal,
Hal, and nisin at pH 7.5 using HPLC and MS analysis. (b) Bio-
assay against Lactococcus lactis HP using the same samples as
analyzed by HPLC in panel a. The day of incubation is denoted
above each well. Haloduracin: upper left (blue), nisin: lower left
(red), nisin standards: right (yellow).
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Moreover, at pH 7 and 8, essentially complete degrada-
tion was observed in 10 days (27).
Haloduracin was discovered during a search for alka-
liphilic lantibiotic-producing bacteria. Its producer, Ba-
cillus halodurans C-125, ﬂourishes in basic environ-
ments with a pH greater than 9.5. For this reason, we
speculated that haloduracin may have improved chemi-
cal stability compared to nisin at neutral pH. We moni-
tored the stability of Hal, Hal, and nisin in a solution
of low buffer concentration at pH 7.5 using HPLC and
MALDI-TOF MS analysis (Figure 3, panel a). Hal dis-
played remarkable stability with 90% of intact pep-
tide remaining after 36 days. The globular nature of this
peptide, in addition to its low number of residues ca-
pable of undergoing oxidation, may contribute to its
overall stability. Hal showed moderate stability as
compared with Hal, and the degradation of this linear
peptideoccurredgraduallyoverthecourseofthisassay.
MS analysis of the additional peaks that were observed
by HPLC shows that the products are mostly the result
of oxidation (M  16); breakdown of the oligopeptide
chainwasnotobserved.Nisindisplayedthepooreststa-
bility of the three with many oxidation products ob-
served at early time points followed by signiﬁcant
degradation of the peptide chain. The increased suscep-
tibility toward oxidation of both Hal and nisin may be
due to their high number of thioether bridges. Agar dif-
fusion assays were utilized to evaluate the antimicro-
bial activities of haloduracin and nisin over time, using
the same samples that were analyzed by HPLC. As
shown in Figure 3, panel b, oxidation and degradation
of nisin appears to have a much stronger deleterious ef-
fect on its bioactivity than oxidation of Hal has on the
antimicrobialactivityofhaloduracin.Theobservedactiv-
ity is not due to solo activity of Hal, because Hal has
much weaker activity in the absence of Hal. It appears,
therefore,thatthestructuralrequirementsforHalactiv-
ity are not critically dependent on unoxidized thioether
cross-links.
Hal and Hal Act Sequentially To Affect Target
Cells. To address the potential roles of the individual
peptides of haloduracin, we examined the order of bind-
ing events required to observe cell growth inhibitory ac-
tivity. When target cells were incubated with Hal, fol-
lowed by stringent washing to remove unbound peptide
and subsequent incubation with Hal, growth inhibi-
tion was observed (Figure 4, panel a). When the order
of addition was reversed and cells were ﬁrst exposed
to Hal, washed, and then treated with Hal, growth in-
hibition was not observed (Figure 4, panel b). When
Hal and Hal peptides were added at the same time,
growth inhibition was observed (data not shown). The
described outcome of sequential addition is similar to
that observed for the two-peptide lantibiotic lacticin
3147 (21) and suggests a scenario in which Hal binds
Figure 4. Sequential activity of haloduracin peptides against L. lactis HP. Growth curves are shown for (a) Hal treat-
ment, washing, and Hal addition and (b) Hal treatment, washing, and Hal addition. When errors bars are not
visible, the error was smaller than the size of the symbol used.
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the resulting complex is required for Hal to exert its
synergistic effect.
Membrane Depolarization by Haloduracin. Given the
known pore-forming activity of several lantibiotics, we
examinedtheeffectofhaloduracinonmembranepoten-
tial via ﬂow cytometry with DiOC2, a membrane-
potential-sensitive dye. Under physiological conditions,
bacteria with intact cytoplasmic membranes maintain a
membrane potential on the order of 100200 mV (28).
As shown in Figure 5, haloduracin rapidly (within 10
min) dissipated the membrane potential of B. subtilis
cells in a concentration-dependent manner and at lev-
els comparable to or lower than nisin. The extensive dis-
sipation of membrane potential likely reﬂects damage
of the cell membrane.
Pore Formation by Haloduracin and Efﬂux of
Potassium Ions. The effects of haloduracin on mem-
brane potential prompted the investigation of potas-
sium efﬂux using a cell impermeable, potassium-
sensitive dye (PBFI). Treatment of a M. luteus cell
suspension with Hal and Hal triggered rapid efﬂux
of intracellular potassium (Figure 6, panel a). Nearly
identical results were observed for other Gram-positive
strains such as Bacillus subtilis ATCC 6633 (data not
shown). Potassium ion release was detected after a
short lag time followed by a rapid signal increase that
reached a plateau within 45 min. The observed potas-
sium release was dose-dependent, and efﬂux was not
detected in untreated samples. When cells were treated
with Hal or Hal alone at low micromolar concentra-
tions, no leakage of potassium was observed. These
ﬁndings, in addition to the results obtained from the se-
quential binding study described above, prompted us
to further investigate the individual roles of the halodu-
racin peptides in pore formation. When Hal and Hal
were added together or when cells were preincubated
with Hal for 5 min followed by the addition of Hal,a
short lag was observed for 2030 s followed by rapid
K efﬂux. However, when cells were preincubated with
Halfollowed by the addition of Hal, rapid onset of ef-
ﬂux was observed and the lag was essentially absent.
The combined results of potassium efﬂux and sequen-
tial binding assays suggest that the biological role of
Hal involves binding to its target, resulting in a com-
plex that serves as a docking site for Hal to bind and
form pores. A similar mechanism has been proposed for
lacticin 3147 (9), and it may be that this is a general
mechanism for two-peptide lantibiotics for which the
-peptide has structural homology with mersacidin.
Hal Mutants. Antimicrobial activity in the nanomo-
lar range often involves binding to a speciﬁc target mol-
ecule.Onthebasisofthecomparableactivityofhalodu-
racin and nisin (a known lipid II-binding lantibiotic)
againstarangeofbacteria,aswellasthestructuralsimi-
larity of Hal with mersacidin, haloduracin most likely
targets lipid II. The Halpeptide possesses a conserved
CTLTXEC thioether bridge motif (B-ring), which is be-
lieved to be important for lipid II binding (6, 29). This se-
quence is found in several class II lantibiotics including
the single-peptide lantibiotics mersacidin and actagar-
dine, as well as the Ltn peptide from the two-peptide
lantibiotic lacticin 3147 (30−32). Residing within this
ring is a highly conserved glutamate residue, which has
Figure 5. Haloduracin and nisin display comparable
membrane depolarization activities. a) Mean ﬂuores-
cence intensity (MFI) for haloduracin and nisin over a
range of concentrations. b) Representative histogram
of cell count versus DiOC2 ﬂuorescence intensity for
haloduracin. Populations shown are for 0 nM (control,
black), 25 nM (red), 250 nM (blue), 2.5 M (violet), and
25 M haloduracin (green).
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to lipid II (33).
Haloduracin biosynthesis was recently reconstituted
in vitro (6), providing a method for the production of
haloduracin mutants (29). The effects of individually dis-
rupting the B- and C-thioether rings of Halwere probed
bythemutationofCys23andCys27toalanines,respec-
tively. Additionally, the conserved glutamate residing in
the conserved CLTXEC ring (B-ring) was mutated to the
isosteric glutamine (Figure 1). It has been shown previ-
ouslythatthesemutationsdonotaffecttheformationof
the other ring structures (29).
All Hal mutants retained the ability to inhibit L. lac-
tis HP cell growth in liquid medium when incubated in
the presence of wild-type Hal. Quantitative IC50 values
highlight the importance of the thioether rings of Halin
the antimicrobial activity of haloduracin with IC50 val-
ues of 335  29 and 1180  48 nM for wild-type Hal
combined with Hal C23A and C27A, respectively. The
highly conserved glutamate residue residing in the
B-ring of Hal also was important but not required for
activity and displayed an IC50 of 964  76 nM for Hal
E22Q in combination with wild-type Hal.
Maintaining biological activity at all despite the ab-
sence of conserved thioether rings present in Hal was
unanticipated as these motifs are generally considered
to be the basis of lantibiotic bioactivity and disruption of
aringhasoftenresultedinabolishedactivity(1,34−39).
The relatively modest reduction of bioactivity of the
highly conserved B-ring mutant (10-fold) was therefore
most unexpected. The retention of activity for the C27A
and E22Q mutants was also unexpected as these mu-
tants had no activity in agar diffusion assays (29). Simi-
lar increased activity of two-peptide lantibiotics in liq-
uid media compared to solid agar media has been
observed previously (40). Additional studies are neces-
sary to investigate whether the reduced potency of Hal
mutants in combination with wild-type Hal is reﬂec-
tive of the ability of Hal mutants to bind lipid II, to ef-
fectively recruit Hal for synergistic activity, or both.
Inhibition of Spore Outgrowth. Nisin inhibits the out-
growth of spores from several pathogenic Gram-positive
bacteria including Bacillus and Clostridium (15, 41). To
determine if haloduracin is capable of preventing spore
outgrowth, Bacillis anthracis (Sterne 7702) was selected
as a model. Spores were germinated in Brain Heart Infu-
sion (BHI) medium in the presence of a range of halodu-
racin concentrations (Figure 7). For cultures containing
low amounts of haloduracin (0.1 M), differential inter-
ference contrast (DIC) microscopy revealed chains of
vegetative bacilli after 5 and 10 h. However, no bacilli
were present within cultures supplemented with 1, 10,
or 100 M haloduracin. This dose-dependent response
shows that haloduracin was equally effective as nisin in
Figure 6. Potassium ion release from Micrococcus luteus cells in-
duced by haloduracin and nisin. (a) Reponses to 10 (blue), 5
(green), 1 (red), 0.25 (orange), and 0 M (gray) haloduracin or ni-
sin. (b) The effects on potassium release by preincubating ei-
ther Hal or Hal prior to addition of its counterpeptide: (A, blue)
5 M Hal preincubation followed by 5 M Hal addition;
(B, green) 5 M Hal preincubation followed by 5 M Hal addi-
tion; (C, red) simultaneous addition of 5 M Hal and 5 M Hal;
(D, orange) addition of 5 M nisin; (E, violet) addition of 5 M
Hal; (F, pink) addition of 5 M Hal; and (G, gray) a control
without haloduracin. Vertical line (black) indicates time of antibi-
otic addition.
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Hal and Hal also inhibited spore outgrowth when in-
cubated independently, but only at 100 M concentra-
tions, whereas vegetative bacilli were observed in cul-
tures containing 10 M or less of either peptide
(Supplementary Figure S5). Hence, the spore outgrowth
inhibition depicted in Figure 7 is the result of a synergis-
tic mechanism of both peptides.
Conclusion. This study illustrates the potent antimi-
crobial activity displayed in a synergistic manner by the
two peptides of haloduracin. The activity of this two-
peptide lantibiotic rivals that of nisin, which has been
used worldwide as an effective preservative against
food-borne pathogens. Haloduracin displayed stability
higher than that of nisin at pH 7, which bodes well for
potential use. Despite signiﬁcant differences in the
structures of both the - and -peptides of lacticin 3147
and haloduracin (Figure 1), these two compounds ap-
pear to operate by a similar mechanism that involves
recognition by the -peptides of a target at the cell sur-
face, likely lipid II, and utilization of the -peptides for
membrane permeabilization. As such, these com-
pounds combine the two activities of nisin into sepa-
rate peptides (42).
METHODS
Materials, Cultures, and Conditions. All chemicals and HPLC
grade solvents were purchased from Sigma-Aldrich, unless oth-
erwise stated. Tris and MOPS buffers were obtained from Fisher
and -cyano-4-hydroxy-cinnamic acid from Fluka. All media in-
cluding Luria Bertoni (LB), Brain Heart Infusion (BHI), Todd He-
witt (TH), Mueller Hinton Broth (MHB), and M17 supplemented
with 0.5% glucose (w/v) (GM17) were purchased from BD Bio-
sciences. Factor Xa was purchased from New England Biolabs.
Supplementary Table S1 describes the bacteria strains, source,
and culture conditions for all bacteria used for this study. All
Hal mutants were prepared as described previously (6, 29).
Speciﬁc Activity Determination. Microtiter plates were used to
determine the IC50 values (the concentration at which 50%
growth inhibition is observed) of indicator strains. For assays
with haloduracin, a 1:1 ratio of Hal:Hal was used. Serial dilu-
tions of Hal and Hal peptides were prepared in sterile deion-
ized water (SDW). Ninety-six-well and forty-eight-well microtiter
plates (Corning Costar) were utilized for anaerobic and aerobic
strains, respectively (see Materials, Cultures, and Conditions
above). For 96-well plates, the total volume of culture in each
well was 200 L; the experimental wells contained 50 Lo fd i -
luted Hal and Hal peptides at deﬁned concentrations and
150 L of a 1-in-10 dilution (approximately 1  108 CFU mL1)
of a culture of indicator strain diluted in fresh growth medium. In
addition, each plate contained several blank (150 L fresh
growth medium and 50 L SDW) and control wells (150 Lo f
untreated 1-in-10 diluted culture and 50 L SDW). For 48-well
plates, the total volume in each well was 300 L; the experimen-
tal wells contained 75 L of diluted Hal and Hal peptides at
deﬁned concentrations and 225 L of a 1-in-10 dilution (ap-
proximately 1  108 CFU mL1) of a culture of indicator strain di-
luted in fresh growth medium. In addition, each plate con-
tained several blank (225 L fresh growth medium and 75 L
SDW) and control wells (225 L of untreated 1-in-10 diluted cul-
ture and 75 L SDW). The optical density at 600 nm (OD600)
was recorded at hourly intervals from 0 to 5 h with an addi-
tional measurement at 18 h using a BioTek Synergy 2 plate
reader. Plates were incubated according to optimal growth con-
ditions (see Materials, Cultures, and Conditions above). The trip-
licate readings were averaged, and blanks (growth medium
and SDW only) were subtracted from these readings. Growth
curves were developed using control (culture and SDW only)
readings to ensure sufﬁcient OD changes for accurate inhibi-
tion assessment. Curve ﬁts for IC50 determination were
produced by ﬁtting the data with Origin8 software using the
doseresponse curve with the equation y 	 A1  (A2  A1)/(1
 10(Log x0  x)p), with p 	 variable Hill slope. A 50% growth inhi-
bition was determined as half the ﬁnal OD600  0.05. Nisin IC50
values were determined using identical procedures as described
above.
Speciﬁc activities for individual peptides were determined es-
sentially as described above, except that peptides were evalu-
ated independently. Speciﬁc activity was assessed against the
indicator strain L. lactis HP, and nisin standards were used as
controls.
Membrane Potential Assays. Membrane potential was mea-
sured indirectly using the membrane potential-sensitive dye,
3,3=-diethyloxacarbocyanine iodide (DiOC2, Molecular Probes/
Invitrogen). B. subtilis ATCC 6633 cultures (in triplicate) were
grown to a density of 4  106 cells mL1, and aliquots were
transferred to tubes containing DiOC2 (ﬁnal concentration of 300
nM). Cells were incubated with the dye for 20 min at 30 °C un-
der aeration conditions prior to the addition of either halodura-
cin or nisin at 25 M, 2.5 M, 250 nM, 25 nM, or 0 nM. Follow-
ing addition of peptides, cultures were incubated at 30 °C with
aeration for an additional 10 min prior to analysis. The mem-
brane potential was assessed by measuring the B. subtilis-
associated DiOC2 ﬂuorescence by ﬂow cytometry (BD Bio-
sciences LSR II ﬂow cytometer) with excitation at 488 nm with
an argon laser and measurement of emission through a band-
pass ﬁlter at 530/30 nm. A minimum of 50,000 events were de-
Figure 7. Inhibition of Bacillus anthracis spore out-
growth by haloduracin. Scale bars equal 5.0 m for all
images.
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FCS Express 3.00.0311 V Lite Stand-alone software. The data
were plotted as the geometric mean of the ﬂuorescence inten-
sity (MFI).
Potassium Ion Release Assay. Potassium efﬂux was mea-
sured using the K-sensitive ﬂuorescent dye 1,3-benzenedi-
carboxylic acid, 4,4=-(1,4,10,13-tetraoxa-7,16-diazacyclo-
octadecane-7,16-diylbis(5-methoxy-6,2-benzofurandiyl))bis
(PBFI, Molecular Probes/Invitrogen). A culture of M. luteus was
grown to an OD600 of 1.0 and washed ﬁve times with assay
buffer (5 mM HEPES, 5 mM glucose, pH 7.2). Washed cells were
resuspended in one-ﬁfth the volume of assay buffer containing
PBFI (ﬁnal concentration of 10 M) and aliquots were added to
UV-transparent microtiter plates (Nunc). Sample ﬂuorescence
(excitation 	 346 nm, emission 	 505 nm) background data
was collected (BioTek Synergy 2 plate reader, excitation ﬁlter
360/40, emission ﬁlter 508/20) until baseline signal was
achieved, followed by the addition of haloduracin (Hal and
Hal in a 1:1 ratio) or nisin at 10 M, 5 M, 1 M, 250 nM, or
0 nM. For preincubation studies of the haloduracin peptides,
baseline signal was achieved, followed by the addition of ei-
ther Hal or Hal to wells at the concentrations indicated and
incubation for 5 min prior to the addition of Hal or Hal,
respectively.
Inhibition of Bacillus anthracis Spore Outgrowth. B. anthracis
spores at a concentration of 4.0  106 spores mL1 were incu-
bated in Brain Heart Infusion (BHI) medium supplemented with
haloduracin (0.1, 1, 10, or 100 Ma taH a l :Hal ratio of 1:1) or
0.1 M MOPS (pH 6.8) as a control. For assessment of Hal and
Halused independently, spores were incubated in BHI medium
supplemented with the peptide at 0.1, 1, 10, or 100 Mo r
with 0.1 M MOPS (pH 6.8) as a control. As a positive control,
spores were treated with nisin under the same conditions and
concentrations as used for Hal and Hal. Cultures were incu-
bated at 37 °C under aeration conditions and ambient CO2
(0.03% CO2). At 0, 5, and 10 h, samples were removed from
the B. anthracis cultures and ﬁxed by incubation in 3% formal-
dehyde (v/v) for 30 min at 37 °C. Samples were mounted on
glass microscope slides in 20% glycerol (v/v). Differential inter-
ference contrast (DIC) microscopy images were collected with an
Applied Precision assembled DeltaVision epiﬂuorescence micro-
scope equipped with an Olympus Plan Apo x100 oil objective
with a numerical aperture of 1.42 and a working distance of
0.15 mm. Images were processed with SoftWoRX Explorer Suite.
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